Generic drugmaker Mylan NV, citing media speculation that Teva Pharmaceutical Industries Ltd might be eyeing it as a takeover target, says it doubts that regulators would approve such a deal and is committed to its current strategy as a stand-alone company.
In a news release on Friday, Mylan said that it has not received an offer and described the idea that Teva might want to buy it as a rumor.
The Dutch company said anti-trust regulators would probably not approve a deal between Mylan and Teva, because their businesses overlap in major ways. It said it would thoroughly examine an offer if it received one.
Teva did not immediately respond to a request for comment.
Shares of Mylan rose US$2.98, or 4.5 percent, to US$69.82. Earlier they spiked up as much as 8.7 percent. Teva Pharmaceutical shares gained US$1.42, or 2.2 percent, to US$64.91.
Earlier this month, Mylan offered to buy generic drug and ingredients maker Perrigo Co for about US$29 billion, or US$205 per share. Perrigo, which is based in Ireland, said it would review Mylan’s offer. Mylan says the companies would have US$15.3 billion in combined revenue this year.
Teva has about US$20 billion in annual revenue, and its executives have spoken recently about their interest in making new acquisitions and consolidating some of the largest companies in the generic drug industry.
“We are ready to take on a transaction,” Teva head of generics business Sigurdur Olafsson said at a healthcare conference last month.
In a research note written earlier this month, Barclays analyst Douglas Tsao said Teva believes that some of the largest generic drug companies should combine their businesses, because they could save a lot of money by merging their manufacturing operations.
He said an acquisition of Mylan would “re-establish Teva as the dominant market leader.”
Teva gets almost half of its revenue from generic drugs. It also makes drugs for central nervous system disorders, respiratory illnesses and cancer, as well as over-the-counter medicines. Its biggest-selling product is the multiple sclerosis drug Copaxone. Last month, it agreed to buy Auspex Pharmaceuticals Inc, which is developing central nervous system disorder treatments, for US$3.2 billion.
Mylan shares are up 17 percent since April 7, the day before it went public with its offer for Perrigo, and are near an all-time high.
Shares of contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) came under pressure yesterday after a report that Apple Inc is looking to shift some orders from the Taiwanese company to Intel Corp. TSMC shares fell NT$55, or 2.4 percent, to close at NT$2,235 on the local main board, Taiwan Stock Exchange data showed. Despite the losses, TSMC is expected to continue to benefit from sound fundamentals, as it maintains a lead over its peers in high-end process development, analysts said. “The selling was a knee-jerk reaction to an Intel-Apple report over the weekend,” Mega International Investment Services Corp (兆豐國際投顧) analyst Alex Huang
TRANSITION: With the closure, the company would reorganize its Taiwanese unit to a sales and service-focused model, Bridgestone said Bridgestone Corp yesterday announced it would cease manufacturing operations at its tire plant in Hsinchu County’s Hukou Township (湖口), affecting more than 500 workers. Bridgestone Taiwan Co (台灣普利司通) said in a statement that the decision was based on the Tokyo-based tire maker’s adjustments to its global operational strategy and long-term market development considerations. The Taiwanese unit would be reorganized as part of the closure, effective yesterday, and all related production activities would be concluded, the statement said. Under the plan, Bridgestone would continue to deepen its presence in the Taiwanese market, while transitioning to a sales and service-focused business model, it added. The Hsinchu
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has approved a capital budget of US$31.28 billion for production expansion to meet long-term development needs during the artificial intelligence (AI) boom. The company’s board meeting yesterday approved the capital appropriation plan for purposes such as the installation of advanced technology capacity and fab construction, the world’s largest contract chipmaker said in a statement. At an earnings conference last month, TSMC forecast that its capital expenditure for this year would be at the higher end of the US$52 billion to US$56 billion range it forecast in January in response to robust demand for 5G, AI and
Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) investment project in Arizona has progressed better than expected, but it still faces challenges such as water and labor shortages, National Development Council (NDC) Minister Yeh Chun-hsien (葉俊顯) said yesterday. Speaking with reporters after visiting TSMC’s Arizona hub and attending the SelectUSA Investment Summit in Maryland last week, Yeh said TSMC’s Arizona site turned a profit of NT$16.14 billion (US$514 million) last year in its first full year of mass production. “TSMC told me it was surprised by the smooth trial run of the first fab, which has left the company optimistic about the project’s outlook,”
RSS